Published in J Thromb Haemost on May 09, 2005
A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med (1999) 20.31
Transfusion-associated immunomodulation and universal white cell reduction: are we putting the cart before the horse? Transfusion (1999) 4.83
Is a low transfusion threshold safe in critically ill patients with cardiovascular diseases? Crit Care Med (2001) 3.65
IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding. EMBO J (2001) 2.84
Ferrous-activated nicotinamide adenine dinucleotide-linked dehydrogenase from a mutant of Escherichia coli capable of growth on 1, 2-propanediol. J Bacteriol (1969) 2.66
Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Mol Cell (1999) 2.42
Thrombosis in antithrombin-III-deficient persons. Report of a large kindred and literature review. Ann Intern Med (1992) 2.23
Histocompatibility (HL-A) antigens, lymphocytotoxic antibodies and tissue antibodies in patients with diabetes mellitus. Diabetes (1973) 2.21
Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction? Blood (2001) 2.15
Purification and properties of lactaldehyde dehydrogenase from Escherichia coli. J Biol Chem (1969) 2.11
Biologic effects of leukocytes present in transfused cellular blood products. Blood (1994) 1.65
Generation of a humanized, high affinity anti-tissue factor antibody for use as a novel antithrombotic therapeutic. Thromb Haemost (2001) 1.64
Transfusion-associated bacterial sepsis: the phoenix rises yet again. Transfusion (1994) 1.63
Inhibition of injury induced thromboatherosclerotic lesions by anti-platelet serum in rabbits. Thromb Haemost (1976) 1.60
High level Escherichia coli expression and production of a bivalent humanized antibody fragment. Biotechnology (N Y) (1992) 1.43
Rifampicin-induced immune thrombocytopenia. Br Med J (1970) 1.43
A novel congenital haemostatic defect: combined factor VII and factor XI deficiency. Blood Coagul Fibrinolysis (1992) 1.42
Universal leucocyte-depletion of blood components: cell concentrates and plasma. Vox Sang (2001) 1.39
Characterization of an erythroid precursor cell of high proliferative capacity in normal human peripheral blood. Proc Natl Acad Sci U S A (1977) 1.39
Experimental animal model of refractoriness to donor platelets: the effect of plasma removal and the extent of white cell reduction on allogeneic alloimmunization. Transfusion (1993) 1.38
A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL. Biochemistry (2000) 1.34
Erythroid precursors in congenital hypoplastic (Diamond-Blackfan) anemia. J Clin Invest (1978) 1.33
Crystallization and stoichiometry of binding of a complex between a rat intestinal Fc receptor and Fc. J Mol Biol (1993) 1.22
Universal WBC reduction: the case for and against. Transfusion (2001) 1.21
Do blood transfusions improve outcomes related to mechanical ventilation? Chest (2001) 1.19
Adult hemoglobins are synthesized in erythroid colonies in vitro derived from murine circulating hemopoietic progenitor cells during embryonic development. Proc Natl Acad Sci U S A (1982) 1.13
Erythroid colony induction without erythropoietin by Friend leukemia virus in vitro. Proc Natl Acad Sci U S A (1975) 1.12
Solution structure of the E-domain of staphylococcal protein A. Biochemistry (1996) 1.12
Quantitation of the major fungal allergens, Alt a 1 and Asp f 1, in commercial allergenic products. J Allergy Clin Immunol (2001) 1.09
Structure of the extracellular domain of human tissue factor: location of the factor VIIa binding site. Biochemistry (1994) 1.08
Involvement of Calcium and Calmodulin in Membrane Deterioration during Senescence of Pea Foliage. Plant Physiol (1984) 1.07
Hemoglobin synthesis in human BFU-E and CFU-E-derived erythroid colonies. Blood (1979) 1.06
The inhibition of thrombin-dependent positive-feedback reactions is critical to the expression of the anticoagulant effect of heparin. Biochem J (1987) 1.05
The autoimmune haemolytic anaemias. Br J Haematol (1972) 1.05
An antithrombin III assay based on factor Xa inhibition provides a more reliable test to identify congenital antithrombin III deficiency than an assay based on thrombin inhibition. Thromb Haemost (1993) 1.05
Equilibrium and kinetic measurements of the conformational transition of reduced thioredoxin. Biochemistry (1987) 1.05
Blood component therapy in anaesthetic practice. Can Anaesth Soc J (1983) 1.04
Immunoglobulins in warm-type autoimmune haemolytic anaemia. Lancet (1969) 1.04
Heating greatly speeds Coomassie blue staining and destaining. Biotechniques (2000) 1.04
Structural and mutational analysis of affinity-inert contact residues at the growth hormone-receptor interface. Biochemistry (1996) 1.04
Adult hemoglobins are synthesized in murine fetal hepatic erythropoietic cells. Blood (1983) 1.01
Cytokeratin 18 is expressed on the hepatocyte plasma membrane surface and interacts with thrombin-antithrombin complexes. J Biol Chem (1997) 1.00
Hinge bending within the cytokine receptor superfamily revealed by the 2.4 A crystal structure of the extracellular domain of rabbit tissue factor. Protein Sci (1998) 1.00
The tissue factor region that interacts with substrates factor IX and Factor X. Biochemistry (2000) 0.99
Heparan sulfate and dermatan sulfate inhibit the generation of thrombin activity in plasma by complementary pathways. Blood (1984) 0.98
Common neuroectodermal antigens on human melanoma, neuroblastoma, retinoblastoma, glioblastoma and fetal brain revealed by hybridoma antibodies raised against melanoma cells. Eur J Immunol (1981) 0.97
The 1.85 A resolution crystal structures of tissue factor in complex with humanized Fab D3h44 and of free humanized Fab D3h44: revisiting the solvation of antigen combining sites. J Mol Biol (2001) 0.97
Antibody variable region binding by Staphylococcal protein A: thermodynamic analysis and location of the Fv binding site on E-domain. Protein Sci (1999) 0.97
Tween protects recombinant human growth hormone against agitation-induced damage via hydrophobic interactions. J Pharm Sci (1998) 0.97
Blood product-associated bacterial sepsis. Transfus Med Rev (1991) 0.97
Fab assembly and enrichment in a monovalent phage display system. Biotechnology (N Y) (1991) 0.96
Conformational transitions of thioredoxin in guanidine hydrochloride. Biochemistry (1984) 0.95
Rice (Oryza sativa) allergy in rhinitis and asthma patients: a clinico-immunological study. Immunobiology (2006) 0.94
Hemolytic and pseudo-hemolytic transfusion reactions: an overview of the hemolytic transfusion reactions and the clinical conditions that mimic them. Transfus Med Rev (1994) 0.93
Hemostatic function, survival, and membrane glycoprotein changes in young versus old rabbit platelets. J Clin Invest (1981) 0.91
Allogeneic blood transfusions, immunomodulation, and postoperative bacterial infection: do we have the answers yet? Transfusion (1997) 0.91
Incorporation of 7-deaza dGTP during the amplification step in the polymerase chain reaction procedure improves subsequent DNA sequencing. DNA Seq (1990) 0.90
Bacterial contamination of blood components. Vox Sang (2000) 0.90
Unfractionated heparin inhibits thrombin-catalysed amplification reactions of coagulation more efficiently than those catalysed by factor Xa. Biochem J (1989) 0.90
The tissue factor region that interacts with factor Xa in the activation of factor VII. Biochemistry (2001) 0.90
Overestimation of fetomaternal haemorrhage by the acid-elution technique in mothers with beta-thalassaemia minor. Transfus Med (1991) 0.89
Incorporation of [1-14C]acetate into the lipids of the silkworm Bombyx mori L. Biochem J (1964) 0.89
The inhibition of the anticoagulant activity of heparin by platelets, brain phospholipids, and tissue factor. Br J Haematol (1984) 0.89
Epitope location on tissue factor determines the anticoagulant potency of monoclonal anti-tissue factor antibodies. Thromb Haemost (2000) 0.89
Shortening of the bleeding time in rabbits by hydrocortisone caused by inhibition of prostacyclin generation by the vessel wall. J Clin Invest (1979) 0.89
Risks associated with blood transfusion in newborn infants. Clin Perinatol (1984) 0.88
Anemia associated with rheumatoid disease. Inverse correlation between erythropoiesis and both IgM and rheumatoid factor levels. Arthritis Rheum (1983) 0.88
Normal erythropoietic helper T cells in congenital hypoplastic (Diamond-Blackfan) anemia. N Engl J Med (1978) 0.88
RBC T activation and hemolysis: implications for pediatric transfusion management. Transfusion (2000) 0.88
Purification and characterization of tissue plasminogen activator kringle-2 domain expressed in Escherichia coli. Biochemistry (1989) 0.88
Multiple signaling pathways for Cl(-)-dependent depolarization of mesangial cells: role of Ca2+, PKC, and G proteins. Am J Physiol (1992) 0.88
Identification of serine protease as a major allergen of Curvularia lunata. Allergy (2004) 0.87
Effects of guanidine hydrochloride on the refolding kinetics of denatured thioredoxin. Biochemistry (1986) 0.87
The importance of thrombin inhibition for the expression of the anticoagulant activities of heparin, dermatan sulphate, low molecular weight heparin and pentosan polysulphate. Br J Haematol (1985) 0.87
Prevalence of factor V Leiden in a Canadian blood donor population. CMAJ (1996) 0.87
A prospective study evaluating the lowering of hemoglobin standards for blood donors. Transfusion (1989) 0.87
The blood transfusion effect: characterization of T cell alloantigen-specific receptors by sera from transfused mice. Transplant Proc (1987) 0.87
Crystal structure of the kringle 2 domain of tissue plasminogen activator at 2.4-A resolution. Biochemistry (1992) 0.86
Effect of modulators of erythropoiesis on the hemoglobinization of human erythroid cell cultures. Blood (1982) 0.86
Effect of proteolytic activity of Epicoccum purpurascens major allergen, Epi p 1 in allergic inflammation. Clin Exp Immunol (2008) 0.86
Sensitization to blackgram in patients with bronchial asthma and rhinitis: clinical evaluation and characterization of allergens. Allergy (2006) 0.86
Studies on the blood of an MiV homozygote. Transfusion (1981) 0.86
Increased sulphation improves the anticoagulant activities of heparan sulphate and dermatan sulphate. Biochem J (1987) 0.85
Inhibition of thrombin by antithrombin III and heparin cofactor II in vivo. Thromb Haemost (1995) 0.85
The isolation of prothrombin, Factor IX and Factor X from human Factor IX concentrates. Thromb Res (1984) 0.85
Immunodepletion of human plasma factor VIII. Blood (1980) 0.85
Factor V deficiency and its reversal with gluten restriction. In a patient with celiac disease. Arch Intern Med (1983) 0.85
Activation of factor X and prothrombin in antithrombin-III depleted plasma: the effects of heparin. Thromb Res (1982) 0.85
Identification of a GDP-L-fucose:polypeptide fucosyltransferase and enzymatic addition of O-linked fucose to EGF domains. Glycobiology (1996) 0.84
Novel treatment modalities: new platelet preparations and substitutes. Br J Haematol (2001) 0.84
Envelope glycoprotein of avian hemangioma retrovirus induces a thrombogenic surface on human and bovine endothelial cells. J Virol (1990) 0.84
Substitution of the "group-and-screen" for the full crossmatch in elective operations. Can Anaesth Soc J (1983) 0.84
Effect of allogeneic blood transfusion on solid tumor growth and pulmonary metastases in mice. J Cancer Res Clin Oncol (1992) 0.84
Allergenicity assessment of transgenic mustard (Brassica juncea) expressing bacterial codA gene. Allergy (2006) 0.84
Severe factor VII deficiency caused by mutations abolishing the cleavage site for activation and altering binding to tissue factor. Blood (1994) 0.84
Mechanisms for inhibition of the generation of thrombin activity by sulfated polysaccharides. Ann N Y Acad Sci (1986) 0.84
Substitutes for success. Nat Med (1999) 0.84
Molecular analysis of glycophorin A and B gene structure and expression in homozygous Miltenberger class V (Mi. V) human erythrocytes. Eur J Biochem (1989) 0.84
Quantitation of red cell-associated IgG using an immunoradiometric assay. Transfusion (1985) 0.84